Skip to main content

Advertisement

Table 1 patients’ characteristics and drug regimen

From: Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis

Patients (disease) BMI, kg/m2 Disease duration, months Current use of immunosuppressant drugs
I (DM) 30.5 61 AZA
II (DM) 38.6 60 CQ; MTX; CP
III (DM) 38.2 151 None
IV (PM) 27.9 23 AZA
V (DM) 21.4 75 CQ; CP
VI (DM) 26.5 52 AZA; MTX; Prednisone
VII (PM) 31.4 99 MTX 15
VIII (PM) 32.4 26 AZA; MTX
IX (DM) 23.5 82 MTX
X (DM) 27.4 37 HCQ; AZA
XI (PM) 25.2 38 MMF
XII (DM) 43.0 93 AZA
XIII (DM) 37.7 48 AZA
All patients, mean (SD) 31 (6.6) 65 (35) Not applicable
  1. DM, dermatomyositis; PM, polymyositis; BMI, body mass index; AZA, azathioprine; CQ, chloroquine diphosphate; MTX, methotrexate; CP, cyclosporine; HCQ, hydroxychloroquine sulphate; MMF, mycophenolate mofetil.